home / stock / ganx / ganx news

GANX News and Press, Gain Therapeutics Inc. From 05/18/22

Stock Information
Company Name: Gain Therapeutics Inc.
Stock Symbol: GANX
Market: NASDAQ
Website: gaintherapeutics.com
Menu
GANX GANX Quote GANX Short GANX News GANX Articles GANX Message Board
Get GANX Alerts

News, Short Squeeze, Breakout and More Instantly...
GANX - Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

BETHESDA, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites...
GANX - Gain Therapeutics GAAP EPS of -$0.28 beats by $0.09, revenue of $0.05M beats by $0.01M

Gain Therapeutics press release (NASDAQ:GANX): Q1 GAAP EPS of -$0.28 beats by $0.09. Revenue of $0.05M (-99.1% Y/Y) beats by $0.01M. For further details see: Gain Therapeutics GAAP EPS of -$0.28 beats by $0.09, revenue of $0.05M beats by $0.01M

GANX - Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson’s Disease and Gaucher’s Disease. $34.34 Million in Cash as of March 31, 2022, Provides Runway into Se...

GANX - Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium

BETHESDA, Md., May 11, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites...
GANX - ChemoCentryx, iRhythm top healthcare gainers; Joint, Endo lead losers' pack

Gainers: ChemoCentryx (CCXI) +19%. iRhythm Technologies (IRTC) +16%. Jounce Therapeutics (JNCE) +15%. Grifols (GRFS) +9%. Sensus Healthcare (SRTS) +8%. Losers: Joint (JYNT) -46%. Endo International (ENDP) -34%. Guardant Health (GH) -26%. Gain ...

GANX - Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at XXVII IAPRD World Congress

BETHESDA, Md., May 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company applying its proprietary computational discovery platform to identify novel targets and small molecule treatments, today ann...

GANX - Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

BETHESDA, Md., April 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary ...
GANX - Gain Therapeutics spikes after lab data on Parkinson's Disease candidate

The shares of Gain Therapeutics (NASDAQ:GANX) quickly surged triggering a trading halt on volatility after the development-stage biotech presented pre-clinical data from its Parkinson’s Disease (PD) program for the lead asset GT-02287. According to the results highlighted at a medical ...

GANX - Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at the 2022 Synuclein Meeting

BETHESDA, Md., April 12, 2022 (GLOBE NEWSWIRE) --  Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discove...

GANX - Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference

BETHESDA, Md., March 29, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery pla...
Previous 10 Next 10